Pre-Exposure Prophylaxis

Use of an electronic health record-based intervention significantly increased PrEP use among patients of primary care physicians who care for people with HIV, a randomized trial found.

DENVER — Giving patients the option of choosing long-acting PrEP resulted in a fivefold increase in coverage and a reduction in HIV incidence during the SEARCH trial in Uganda, researchers reported.

DENVER — New data from a cohort of adolescent and young women in sub-Saharan Africa showed a higher level of HIV PrEP adherence than has been reported in previous studies, researchers said.

DENVER — A new study provides reassurances that PrEP can reliably prevent HIV in cisgender women, even if they do not use it daily.

DENVER — Data from the United States and Australia show that PrEP uptake and adherence has increased, and the incidence of HIV has declined in recent years, researchers reported.

Researchers found that implementing generic PrEP programs for young men who have sex with men at risk for HIV — a group known to have adherence and engagement issues — would reduce new infections and be cost-effective.

Clinicians should prescribe pre-exposure prophylaxis to individuals at high risk for HIV to prevent infection with the virus, the U.S. Preventive Services Task Force declared in a final recommendation statement.

In the wake of the FDA approval of the first over-the-counter birth control pill, two experts argued that the time has come to make another prevention medication available without a prescription.

Cisgender women preferred long-acting injectable PrEP over taking a daily pill for HIV prevention by a nearly 4-to-1 margin, according to study findings presented at the International AIDS Society conference.

The federal court ruling against requiring health care insurers to cover PrEP could result in more than 2,000 new and preventable HIV infections among at-risk populations within 12 months of the ruling.